MTSR Metsera Therapeutics Total Debt to Capital

The current share price of Metsera Inc (MTSR) plotted on this chart demonstrates a debt-to-equity ratio of 0.01. The operating model relies on external contractors for the production of biologics, which is offset by strict quality oversight. Management's strategy focuses on developing convenient, long-acting medications. Consequently, Metsera Inc (MTSR) is creating innovative peptide therapies capable of transforming the approach to obesity treatment.

MTSR: Metsera Total Debt to Capital 02/01/2025 - 11/29/2025

Analytical breakdowns and data insights for company Metsera Therapeutics (MTSR)

- price and consensus price forecast:

Price Chart Metsera|MTSR - Forecast Levels Chart

- market capitalization data:

Market Capitalization Metsera|MTSR - Value Adjusted for Debt and Cash

- book capitalization data:

Book Value per Share Metsera|MTSR - Book Capitalization|Market Value to Book Value Ratio metsera.com|MTSR - Aggregate Asset Value

- debt and liquidity data:

Debt to Equity Metsera Inc|MTSR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Metsera Inc|MTSR - Company Aggregate Debts|Debt to Book Value Metsera

Comprehensive company analysis:MTSR - Metsera

This indicator is calculated as the ratio of total liabilities to the market value of equity, measuring the business's degree of reliance on debt financing. On the GURU.Markets platform, the total debt-to-equity ratio allows for an assessment of the financial stability of Metsera Inc. (MTSR) amid a lack of revenue and high costs associated with the final stages of clinical drug trials.

Key competitors

Debt to Equity Ascendis Pharma ASND|Aggregate Debt to Equity Madrigal Pharmaceuticals Inc|Corcept (CORT) - Total Debt to Capital|All Debt to Shareholders' Equity Ratio Rhythm Corp (RYTM)|Total Debt to Capital AKRO (Akero Therapeutics)|moonlaketx.com - Total Debt to Capital|Debt to Equity Crinetics (CRNX)|NAMS: All Debt to Shareholders' Equity Ratio|SLNO (Soleno) - Debt to Equity|Amicus Corp (FOLD) - Total Debt to Equity Ratio|ETNB (89bio, Inc.) - Total Debt to Capital|Total Debt to Capital agios.com (AGIO)|Structure Therapeutics Inc. (GPCR) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio MDXG (MiMedx Group Inc)|Rezolute Corp - Debt to Equity|Total Debt to Equity Ratio Lexicon Corp LXRX|MBX (MBX Biosciences Inc) - Total Debt to Capital|altimmune.com (ALT) - Debt to Capital|AARD - Total Debt to Equity Ratio|Sagimet Biosciences, Inc. (SGMT) - Aggregate Debt to Capital|BIOA (BioAge Labs Inc.) - Total Debt to Capital|Total Debt to Capital Biomea Fusion Corp|Total Debt to Capital Quince Therapeutics (QNCX)|Debt to Equity GUTS (fractyl.com)|VTVT: Debt to Equity|Agape ATP Corp - Debt to Capital|PLUR - Debt to Equity|SYBX - Debt to Equity|Lipocine Inc. - Total Debt to Capital|MTNB (Matinas BioPharma Holdings) - Total Debt to Capital Coefficient|SPRB: Debt to Equity|Total Debt to Capital Coefficient GLTO|Debt to Equity CTCX (Carmell Corp)|Total Debt to Equity Ratio LUMO (Lumos Therapeutics)|Organovo Holdings, Inc. - Debt to Equity|Total Debt to Equity Ratio radiuspharm.com RDUS